Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFa-blocker in patients with active rheumatoid arthritis and active axial and peripheric spondyloarthropathy.

Ghent University Hospital0 sites36 target enrollmentApril 11, 2012

Overview

No summary available.

Registry

who.int

Start Date

April 11, 2012

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

•\- age between 18 and 70 years old
•\- diagnosed with rheumatoid arthrosis according to the ACR\-criteria,
•diagnosed with axial spondyloarthropathy according to the ASAS criteria (of which 5 of them should meet the modified New York criteria),
•diagnosed with peripheral spondylarthropathy
•\- no active tuberculosis
•\- no pregnant women or women who are not using contraceptives when applicable
•\- patients need to understand the study and give informed consent
•OR diagnosed with erosive hand OA
•OR diagnosed with active Crohn's disease
•Are the trial subjects under 18? no

•\- no experimental (non\-) biological therapy in the last 3 months, or within 5 halflives befor baseline visit
•\- no anti\-TNF therapy
•\- no rituximab and/or abatacept
•\- known hypersensitivity vs certolizumab pegol or one of his components
•\- medical history of serious progressive uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebreal diseases
•\- serious or life\-threatening infections over the last 6 months, or signs of current or recent infection
•\- active or latent tuberculosis
•\- known previous or current viral hepatitis B or C
•\- known HIV infection
•\- presence of malignity or history of maligne pathology